Co-Targeting of DTYMK and PARP1 as a Potential Therapeutic Approach in Uveal Melanoma

Sylwia Oziębło, Jakub Mizera, Agata Górska, Mateusz Krzyziński, Paweł Karpiński, Anna Markiewicz, Maria Sąsiadek, Bożena Romanowska-Dixon, Przemysław Biecek, Mai P. Hoang, Antonina Joanna Mazur, Piotr DonizyCells 2024 · DOI

TL;DR

Uveal melanoma (UM), a rare but aggressive eye cancer, currently lacks effective treatments for advanced stages. This study identifies DTYMK and PARP1 as promising therapeutic targets, demonstrating that simultaneously inhibiting both enzymes significantly reduces UM cell growth, proliferation, and migration in vitro, offering a potential new therapeutic strategy.

What Problem Does This Paper Address?

Uveal melanoma (UM) is the most common primary intraocular tumor in adults. While localized UM can be treated, advanced disease with metastases is associated with a grim prognosis and lacks standardized, effective therapies. Immunotherapy, a success in cutaneous melanoma, has shown limited durable responses in UM. This unmet need drives the search for novel molecularly targeted therapies. The authors identified DTYMK (deoxythymidylate kinase) and PARP1 (poly (ADP-ribose) polymerase 1) as potential targets through bioinformatic analysis, noting their roles in DNA metabolism and their overexpression in UM, correlating with poor prognosis.

Methods

The study employed a multi-pronged approach:

  • Bioinformatic and In Silico Analysis: TCGA (The Cancer Genome Atlas) RNA-seq data and single-cell RNA-seq data from UM patients were analyzed to identify potential therapeutic targets and assess their correlation with survival.
  • Immunohistochemistry (IHC): Protein expression levels of DTYMK and PARP1 were quantified in patient tumor samples using H-scores to correlate them with clinical outcomes and BAP1 status.
  • Cell Culture and In Vitro Assays: Two UM cell lines, MP41 (BAP1-positive) and MP46 (BAP1-negative), were used to test the effects of DTYMK and PARP1 inhibitors.
  • XTT Assay: Assessed cell viability and cytotoxicity of individual and combined inhibitors.
  • EdU Incorporation Assay: Measured cell proliferation by quantifying the incorporation of a thymidine analog into newly synthesized DNA.
  • Western Blot: Analyzed the impact of treatments on the PI3K/mTOR signaling pathway by examining the phosphorylation of the S6 ribosomal protein (pS6).
  • Single-Cell Migration Assay: Evaluated cell motility and migration speed using live-cell imaging over 72 hours.
  • Synergy Assessment: The SynergyFinder tool was used to quantitatively assess the synergistic or additive effects of drug combinations.

Datasets

  • TCGA UVM bulk tumor samples: Preprocessed RNA-seq data from 75 UM samples.
  • Gene Expression Omnibus (GEO) database: Single-cell RNA-seq data from 11 UM samples (8 primary, 3 metastatic), comprising over 100,000 cells.
  • Patient Cohort: 164 UM patients diagnosed at the Department of Ophthalmology and Ocular Oncology, Medical College, Jagiellonian University in Krakow, Poland.

Key Insights and Ideas

  • DTYMK and PARP1 as Double-Hit Targets: The core hypothesis is that simultaneously targeting DTYMK (involved in DNA synthesis) and PARP1 (involved in DNA repair) creates a "double hit" to DNA metabolism, overwhelming cancer cells' ability to cope.
  • Synergistic Cytotoxicity: The combination of DTYMK and PARP1 inhibitors showed not just additive but synergistic cytotoxic effects in BAP1-positive MP41 cells, and additive effects in BAP1-negative MP46 cells. This suggests a potent combined therapeutic strategy.
  • Beyond Viability: Impact on Proliferation and Motility: The combined treatment didn't just kill cells; it significantly reduced their ability to proliferate (measured by EdU incorporation) and decreased their motility and migration speed, crucial aspects of cancer progression and metastasis.
  • mTOR Pathway Inhibition: The co-inhibition of DTYMK and PARP1 led to a decrease in phosphorylated S6 protein (pS6), a downstream marker of the mTOR signaling pathway, suggesting a mechanism by which these drugs might suppress cell survival and proliferation.
  • BAP1 Status Doesn't Halt Efficacy: While there were some differences in response between BAP1-positive and BAP1-negative cell lines, the combined DTYMK and PARP1 inhibition demonstrated efficacy across both, indicating a broad potential application.

Key Results

  • DTYMK and PARP1 Overexpression: High levels of DTYMK and PARP1 protein were detected in a significant proportion of UM patients and correlated with poorer overall survival.
  • Inhibitor Efficacy: Pamiparib (PARP1 inhibitor) showed significant cytotoxicity in MP41 cells (IC50 = 29.07 µM) but limited effect in MP46 cells. Ymu1 (DTYMK inhibitor) was more broadly toxic, with IC50 values of 7.49 µM for MP41 and 19.87 µM for MP46.
  • Combined Treatment Superiority: Combinations of pamiparib and Ymu1 demonstrated significantly higher cytotoxicity than individual inhibitors, especially in MP41 cells.
  • Reduced Proliferation: Combined treatment with pamiparib and Ymu1 led to substantial reductions in EdU incorporation (up to 80% in MP41 cells).
  • Decreased Motility: The combined inhibitors reduced cell migration distance and velocity in both cell lines, with a notable impact on directionality in MP46 cells.

Limitations and Future Work

  • In Vitro Focus: All experiments were conducted in vitro using cell lines. The findings need validation in preclinical animal models and ultimately in human clinical trials.
  • Drug Resistance: The paper acknowledges that tumors can acquire resistance to PARP inhibitors, and while DTYMK inhibition might overcome this, further research is needed.
  • Dose Optimization and Scheduling: The authors highlight the need for careful dose optimization and scheduling of combined inhibitors to minimize potential toxicity in vivo.
  • Preclinical and Clinical Exploration: The study strongly advocates for further exploration of this co-targeting strategy in preclinical models and subsequent clinical trials for UM patients.

Summary updated

Abstract

Uveal melanoma (UM) is the most common primary intraocular tumor in adults, with no standardized treatment for advanced disease. Based on preliminary bioinformatical analyses DTYMK and PARP1 were selected as potential therapeutic targets. High levels of both proteins were detected in uveal melanoma cells and correlated with increased tumor growth and poor prognosis. In vitro tests on MP41 (BAP1 positive) and MP46 (BAP1 negative) cancer cell lines using inhibitors pamiparib (PARP1) and Ymu1 (DTYMK) demonstrated significant cytotoxic effects. Combined treatment had synergistic effects in MP41 and additive in MP46 cell lines, reducing cell proliferation and inhibiting the mTOR signaling pathway. Furthermore, the applied inhibitors in combination decreased cell motility and migration speed, especially for BAP1-negative cell lines. Our hypothesis of the double hit into tumoral DNA metabolism as a possible therapeutic option in uveal melanoma was confirmed since combined targeting of DTYMK and PARP1 affected all tested cytophysiological parameters with the highest efficiency. Our in vitro findings provide insights into novel therapeutic avenues for managing uveal melanoma, warranting further exploration in preclinical and clinical settings.
BibTeX
@inproceedings{oziebo2024co,
  author = {Sylwia Oziębło and Jakub Mizera and Agata Górska and Mateusz Krzyziński and Paweł Karpiński and Anna Markiewicz and Maria Sąsiadek and Bożena Romanowska-Dixon and Przemysław Biecek and Mai P. Hoang and Antonina Joanna Mazur and Piotr Donizy},
  title = {{Co-Targeting of DTYMK and PARP1 as a Potential Therapeutic Approach in Uveal Melanoma}},
  booktitle = {Cells},
  year = {2024},
  doi = {10.3390/cells13161348},
}
Figure